Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 425 (CSE: BBM) (CSE: XCX) (OTC: VSYM) (TSX: APHA) (NASDAQ: APHA)
Delta, Kelowna, BC - June 8, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 425 (CSE: BBM) (CSE: XCX) (OTC: VSYM) (TSX: APHA) (NASDAQ: APHA)
Today's podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today's podcast we will be looking at a few public company announcements.
Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, announced that its wholly-owned subsidiary Blueberries SAS entered into a collaboration agreement with Medicanmentos de Cannabis SAS, to develop, and produce Tetrahydrocannabinol ("THC") cannabis extracts for the international market.
Blueberries will develop a Research and Development project with medcann to produce commercial THC dominant extracts. The Company will utilize its extraction capabilities to process the THC dominant cannabis flower cultivated by medcann. In 2018, medcann became the first and only company to obtain the registration of psychoactive varieties of cannabis in Colombia.
Both companies will work together in the manufacturing and commercialization, taking advantage of market dynamics and the commercial THC quotas to be assigned to Blueberries.
In Q1, 2020, Blueberries commissioned its first extraction line at its 2,800 m2 (30,138 sf) state-of-the-art extraction facility located in a modern and secure industrial park 30 minutes outside of Bogota. The first extraction line is fully operational, and the newly commissioned equipment has sufficient capacity to process biomass from Blueberries' own cultivation operations, its contract growers, and other associated licensed producers such as medcann.
The facility uses supercritical CO2 extraction technology to produce the highest quality cannabis oil and has been designed with the flexibility to also employ ethanol extraction technologies to match market demand. The current extraction capacity exceeds the 70,000kg/year of dried flower with the ability to accommodate significant future expansion with additional extraction lines. The Blueberries team is heavily focused on establishing a best-in-class extraction operation with the goal of becoming a leading extraction center in Latin America and an international supplier of medicinal-grade cannabis oil extracts, active pharmaceutical ingredients and related products.
The installed Vitalis extraction line is the first equipment of its kind in Colombia having stainless-steel compressor and extraction vessels, built to stringent European Union - Good Manufacturing Practices standards. The Company's facility is designed to comply with EU-GMP standards to ensure standardization and consistency of production. Blueberries is currently implementing full EU-GMP standards at its extraction facility and expects to commence the certification process shortly which would permit additional export potential to international markets.
"We're excited to partner with medcann. Our team knows that the best results are delivered when great people come together to collaborate with a common vision. This is precisely the environment we have with the team at medcann," said Camilo Villalba, Chief Executive Officer of Blueberries. "We are just starting. As we continue to develop and introduce unique THC extracts based on proprietary genetics from medcann in the coming months, we will have fully leveraged this opportunity to establish a leading position in the cannabis extracts markets."
medcann has established its outdoor agricultural operations in the flattest area of Colombia, the Eastern plains that account for more than 1/3 of the country, a 100% natural and sustainable agroindustry operation with an exceptionally low cost per gram of dried flower and with the fastest and most cost-efficient expansion ability. With more than 800 hectares available upon demand developed through a significant number of small growers, medcann's operations generate a positive social impact with sustainable formal employment.
For medcann, as the leading company in regulatory milestones in Colombia, the Partnership represents a new advance in the development of the medicinal cannabis industry. "Each day we become more convinced of the substantial contribution that the cannabis sector can make to the recovery of the economy in these times of crisis. This agreement confirms medcann's regulatory and agronomic potential as a driver of change of the industry, as companies rely on complementary expertise as a key input to develop joint products" said Jon Ruiz, President of medcann.
AMP German Cannabis Group Inc. (CSE: XCX) announced that it is developing medical brands for a range of cannabis flower strains, extracts and other novel dosage forms specifically for the German market supplied by foreign licenced medical cannabis producers. Licensed producers that have been EU-GMP certified will cultivate medical cannabis to AMP's brand specifications and quality standards.
First large imports of AMP's medical cannabis brand are expected to be coming from
Canada during the fall of 2020 from licenced producers that were EU-GMP certified prior to COVID-19 pandemic. AMP only enters into supply agreements with Canadian licenced producers who can supply a minimum of 1,000 kg annually of AMP branded medical cannabis, shipped on a monthly basis. AMP is in negotiations with several Canadian licenced producers to begin shipments in the fall of this year.
AMP is advancing its other signed Canadian producers to be EU-GMP audited during the fall of 2020 by the Company's German pharmaceutical consultant and inspected for certification during early 2021 by TLV (the Thuringian State Office for Consumer Protection) provided international travel restrictions are normalized. Because of the COVID-19 pandemic, Germany is not conducting inspections of foreign medical cannabis producers until the end of 2020.
To meet future demand as the German market grows, AMP is developing long-term supply sources in Europe for large scale supply of AMP medical cannabis branded products. The Company believes as the German market develops, Europe will become an important and significant medical cannabis supply source. AMP's strategy is to develop exclusive relationships with large medical cannabis licenced producers in certain EU countries for AMP medical cannabis branded products for the German market.
AMP's non-exclusive distribution agreement (see press release dated 16th October 2019) with a leading distributor of pharmaceuticals products to more than 13,000 pharmacies throughout Germany encompasses purchasing AMP medical cannabis branded products. In addition, under our lead pharmaceutical distributor's program, AMP will be investing in physician and pharmacist's education seminars across Germany about medical cannabis. The Company is also in negotiations with additional pharmaceutical distributors to purchase AMP medical cannabis branded products as AMP's imports increases this fall.
Dr. Stefan Feuerstein, Director of AMP, commented: "We had hoped to fulfill our distribution agreement with our lead pharmaceutical distributor in regards to imports from the Netherlands this month but we are optimistic that the Netherlands will resolve its export quota to Germany and increase exports in the near future. As already mentioned, we are in advanced negotiations with several foreign cannabis producers who already have an EU-GMP certification and are expecting to sign at least one definitive supply agreement within the next four weeks. Beginning this fall, AMP will be selling AMP branded medical cannabis products imported from Canada into Germany."
Panaxia Labs Israel Ltd. (TASE: PNAX) traded up following their announcement of strong financial results. Dr. Dadi Segal, CEO of Panaxia Global, said, "Panaxia started 2020 with a strong quarter boasting expanded operations, record quarterly revenues, and a shift to gross profit. Concurrently with increasing the number of patients in Israel, we are on track to initiate export and commercial sales in Europe later this year. We have reached several strategic and financial achievements in the first quarter, including progress in the regulatory registration of our products in Germany and Denmark."
Dr. Segal continued, "We look forward to receiving the export license to start exporting to these and other target countries immediately. Even if the export license is delayed, we believe the completion of the production facility in Malta will allow us to expand our sales to Europe, as a provisional alternative until exports from Israel begin."
In the first quarter of 2020, the Israeli subsidiary, Pharmaceutical company Panaxia Labs Israel Ltd., the largest manufacturer of medical cannabis products in Israel, reports record revenues of 12.2 million, an increase of approx. 83% compared with the revenues in the fourth quarter of 2019, and a 365%-increase (over X4 times) compared with the revenues in the first quarter of 2019. The consecutive, 10-quarter revenue growth is attributed to the expansion of the production, marketing, and home deliveries operations, as well as to the transition of working under the new Israeli cannabis regulation, which provides the Panaxia Israel with higher revenues per product unit. During the first quarter, Panaxia Israel continued to expand its patient base, as well as the number of products it delivered. The company estimates that the COVID-19 crisis, which started in the last two weeks of the quarter, has helped reinforce this trend with an additional increase in demand for products and home deliveries.
During the quarter, the company announced it had entered a first-of-a-kind collaboration agreement in the medical cannabis industry, with Neuraxpharm, Europe's largest CNS therapies company. It covers the commercialization and distribution of Panaxia's advanced cannabis products in Germany as part of Neuraxpharm's broad therapy portfolio.
Cash and cash equivalents, as of March 30, 2020, were 17.6 million, compared with 14.3 million in cash and cash equivalents as of December 31, 2019. The increase is primarily due to the closing of a 17 million private placement of ordinary shares and warrants, led by MORE Investment House and another accredited/institutional investor. The amount is net of a loan repaid to the parent company.
Subsequent to the end of the first quarter, in April 2020, the company strengthened its balance sheet through a total of 12 million in private placements of ordinary shares and warrants to the company's controlling shareholders and to long-term investors, including the chair, Mr. Jonathan Kolber, CEO Dr. Dadi Segal, and Mr. Ran Nussbaum and others.
View Systems, Inc.'s (OTC: VSYM), medical marijuana and hemp subsidiary, Sannabis S.A.S. released information on their Work from Home program designed to capture the recently out of work professionals with the skills to build a business in a nascent industry. Sannabis' Indigenous partners began making cannabis-based products since 2014 under the Sannabis brand. These products have anecdotal evidence of being effective for thousands of patients around the world as evidenced by the hundreds of testimonials the company has received and will be posting online.
Sannabis assisted in the treatment of adults and children with epilepsy, cancer, skin ailments, fibromyalgia, and many more diseases that caused despair since nothing else worked for them, until they were introduced to Sannabis. The company will now capitalize on the goodwill of their brand.
Sannabis Business Partners (SBP) will be given an activation code after their first US$ 40 purchase and have their personal and bank deposit details registered with Sannabis. A minimum $40/month purchase is required to maintain their code active. They simply give their code to their customer to buy direct from Sannabis' online store. Once their customers payment is finalized, the SBP gets a direct transfer from Sannabis, and drop ships the products directly to the customer. As long as SBP maintains an active code, they will receive commission deposits after every purchase by that customer.
Sannabis Business Partners (SBP) will be given the opportunity to generate income from 5 different avenues of compensation.
-No. 1: Sannabis Business Partners earn a 20% commission for the purchases made by their customers that buy directly from Sannabis.
-No.2: SBP earn a 30% commission for the initial purchase made by a new SANNABIS ASSOCIATE PARTNER (SAP) they activate (must be trained by SBP before activation).
-No. 3: SBP earn a 10% commission for each purchase made by the customers of their SANNABIS ASSOCIATE PARTNER referrals.
-No. 4: SBP earn a 20% commission for the purchases made by the SANNABIS ASSOCIATE ENTREPENUER after the first purchase (activation), that will surely continue using the products, so they will continue to earn!
-No. 5: SBP will earn a legal renumeration when they refer patients to our Dr. Sannabis web portal.
"I'm very happy to be providing an income opportunity to many people currently out of work," stated Juan Pablo Guzman, Director of Sannabis S.A.S.
John Campo, President of View Systems, Inc. added, "our office in Cali is working hard to activate as many people as soon as possible so they start generating income for themselves and for the Company."
Aphria Inc. (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company, announced today will be its first day of trading on The Nasdaq Global Select Market ("Nasdaq"), as previously communicated on May 26, 2020, and will continue to be listed under the ticker symbol "APHA." This transition will not impact the Company's primary listing on the Toronto Stock Exchange (TSX: APHA).
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
Download our Mobile App for iPhone and Android